These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20171968)

  • 61. Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor.
    Somerville RP; Devillier L; Parkhurst MR; Rosenberg SA; Dudley ME
    J Transl Med; 2012 Apr; 10():69. PubMed ID: 22475724
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Good Manufacturing Practice-Compliant Production and Lot-Release of
    Wiesinger M; Stoica D; Roessner S; Lorenz C; Fischer A; Atreya R; Neufert CF; Atreya I; Scheffold A; Schuler-Thurner B; Neurath MF; Schuler G; Voskens CJ
    Front Immunol; 2017; 8():1371. PubMed ID: 29123521
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies.
    Singh N; Perazzelli J; Grupp SA; Barrett DM
    Sci Transl Med; 2016 Jan; 8(320):320ra3. PubMed ID: 26738796
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Photothermal Prussian blue nanoparticles generate potent multi-targeted tumor-specific T cells as an adoptive cell therapy.
    Sweeney EE; Sekhri P; Muniraj N; Chen J; Feng S; Terao J; Chin SJ; Schmidt DE; Bollard CM; Cruz CRY; Fernandes R
    Bioeng Transl Med; 2024 May; 9(3):e10639. PubMed ID: 38818122
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination.
    Redeker A; Arens R
    Front Immunol; 2016; 7():345. PubMed ID: 27656185
    [TBL] [Abstract][Full Text] [Related]  

  • 66. T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients.
    Klaver Y; van Steenbergen SC; Sleijfer S; Debets R; Lamers CH
    Front Immunol; 2016; 7():648. PubMed ID: 28082983
    [TBL] [Abstract][Full Text] [Related]  

  • 67. T cell-responsive macroporous hydrogels for in situ T cell expansion and enhanced antitumor efficacy.
    Bhatta R; Han J; Liu Y; Bo Y; Wang H
    Biomaterials; 2023 Feb; 293():121972. PubMed ID: 36566554
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Adoptive T cell therapy: Addressing challenges in cancer immunotherapy.
    Yee C
    J Transl Med; 2005 Apr; 3(1):17. PubMed ID: 15860133
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Dendritic cell-mimicking scaffolds for ex vivo T cell expansion.
    Kim HS; Ho TC; Willner MJ; Becker MW; Kim HW; Leong KW
    Bioact Mater; 2023 Mar; 21():241-252. PubMed ID: 36157246
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficient lentiviral transduction method to gene modify cord blood CD8
    Lo Presti V; Cornel AM; Plantinga M; Dünnebach E; Kuball J; Boelens JJ; Nierkens S; van Til NP
    Mol Ther Methods Clin Dev; 2021 Jun; 21():357-368. PubMed ID: 33898633
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Protocol for generation of human peptide-specific primary CD8
    Grant EJ; Gras S
    STAR Protoc; 2022 Sep; 3(3):101590. PubMed ID: 35942343
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies.
    Lloyd A; Vickery ON; Laugel B
    Front Immunol; 2013; 4():221. PubMed ID: 23935598
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Improved Expansion and
    Medvec AR; Ecker C; Kong H; Winters EA; Glover J; Varela-Rohena A; Riley JL
    Mol Ther Methods Clin Dev; 2018 Mar; 8():65-74. PubMed ID: 29687031
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Artificial 3D Culture Systems for T Cell Expansion.
    Pérez Del Río E; Martinez Miguel M; Veciana J; Ratera I; Guasch J
    ACS Omega; 2018 May; 3(5):5273-5280. PubMed ID: 30023914
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Biosprayed spleen cells integrate and function in mouse models.
    Carter NA; Jayasinghe SN; Mauri C
    Analyst; 2011 Sep; 136(17):3434-7. PubMed ID: 21451871
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Influence of Culture Conditions on Ex Vivo Expansion of T Lymphocytes and Their Function for Therapy: Current Insights and Open Questions.
    Sudarsanam H; Buhmann R; Henschler R
    Front Bioeng Biotechnol; 2022; 10():886637. PubMed ID: 35845425
    [No Abstract]   [Full Text] [Related]  

  • 77. Adoptive transfer of tumor-specific Th9 cells eradicates heterogeneous antigen-expressing tumor cells.
    Sek K; Chan CW; Beavis PA; Darcy PK
    Cancer Cell; 2021 Dec; 39(12):1564-1566. PubMed ID: 34739846
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Coating with flexible DNA network enhanced T-cell activation and tumor killing for adoptive cell therapy.
    Zhang Z; Liu Q; Tan J; Zhan X; Liu T; Wang Y; Lu G; Wu M; Zhang Y
    Acta Pharm Sin B; 2021 Jul; 11(7):1965-1977. PubMed ID: 34386331
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Autolymphocyte therapy-1. In vivo tumor-specific adoptive cellular therapy of murine melanoma and carcinoma using ex vivo activated memory T-lymphocytes.
    Eur J Cancer; 1998 May; 34(6):946. PubMed ID: 9840962
    [No Abstract]   [Full Text] [Related]  

  • 80. Optimization manufacture of virus- and tumor-specific T cells.
    Lapteva N; Vera JF
    Stem Cells Int; 2011; 2011():434392. PubMed ID: 21915183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.